BioTime and Asterias Biotherapeutics announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias.
Asterias Biotherapeutics is dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer. Based in Menlo Park (California, USA), the company is focused on advancing two clinical-stage programs which have the potential to address areas of high unmet medical need in the fields of neurology and oncology.
OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.
VAC2 (antigen-presenting allogeneic dendritic cells) is an allogeneic cancer immunotherapy. The company’s research partner, Cancer Research UK, has commenced a first-in-human clinical trial of VAC2 in non-small cell lung cancer.
Headquartered in Alameda (California, USA), BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. Its pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. The company develops clinical program Renevia, an investigational medical device as an alternative for whole adipose tissue transfer procedures.